NRx Says New Formulation of IV Ketamine Could Be Delivered Subcutaneously

April 15, 2024

DEA to Convene Hearing on Two Little-Known ‘Phenethylamine Hallucinogens’

April 12, 2024

Silo Pharma to Acquire Exclusive Licensing for Alzheimer’s Therapeutic from Columbia University

April 10, 2024

Psilera Appoints Magali Haas to Board of Directors

April 8, 2024

Clairvoyant Expects to Bring Psilocybin Treatment to Market By 2025

April 5, 2024

MIRA Pharmaceuticals Shares Encouraging Pre-Clinical Results for Ketamir-2

April 2, 2024